Lantern Pharma gets USPTO Notice of Allowance for LP—284
Lantern Pharma received a USPTO Notice of Allowance for a patent covering LP—284 to treat mantle cell lymphoma and double-hit lymphoma, including combo regimens and routes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lantern Pharma gets USPTO Notice of Allowance for LP-284 patent
Lantern Pharma said the USPTO issued a Notice of Allowance for its LP—284 treatment patent application for aggressive B—cell lymphomas.